Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). [electronic resource]
Producer: 20100121Description: 32-7 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Boronic Acids -- adverse effects
- Bortezomib
- Case-Control Studies
- Demography
- Disease Progression
- Dose-Response Relationship, Drug
- Female
- France
- Humans
- Male
- Melphalan -- administration & dosage
- Middle Aged
- Multiple Myeloma -- drug therapy
- Pyrazines -- adverse effects
- Stem Cell Transplantation
- Survival Analysis
- Transplantation Conditioning
- Transplantation, Autologous
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.